This page contains press release content distributed by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs

MIAMI, FL / ACCESS Newswire / July 11, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1) related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects.

SKNY-1 is being developed as a potential oral treatment for obesity and addiction. It has previously been shown to achieve up to 30% weight loss, reverse high-calorie food and nicotine cravings, and preserve muscle mass in preclinical models. These new findings suggest that SKNY-1 may deliver these therapeutic effects without emotional or behavioral disruption, an important factor in long-term treatment adherence.

“These findings are a significant step forward,” said Erez Aminov, Chief Executive Officer of MIRA. “The ability to suppress appetite and cravings while reversing anxiety-like effects is critical. These results reinforce the differentiated approach behind SKNY-1 and its potential role as a novel oral treatment in large, underserved markets.”

About the Study

The study used the light-dark preference test in zebrafish-a validated behavioral model to assess anxiety-related responses. Zebrafish naturally prefer darker environments due to an innate fear of predators. However, when anxiety levels are elevated, they avoid the light even more strongly spending more time in the dark. Reduced dark preference (i.e., more time in the light) is interpreted as a calming effect.

Four groups were evaluated:

  • Control Group (No Drug): Fish showed balanced behavior between light and dark environments.

  • CP55,940 Group (CB1 Agonist): These animals spent significantly more time in the dark, confirming that CB1 activation increases anxiety at higher doses. Interestingly, at lower doses, CP55,940 produced a calming effect-reducing dark preference and encouraging exploration of the light area.

  • Rimonabant Group (CB1 Inverse Agonist): Fish treated with Rimonabant also showed increased dark-zone time and exhibited a greater increase in anxiety-like behavior than the CB1 agonist group, under both high and low doses of agonist-consistent with the known psychiatric effects that led to Rimonabant’s market withdrawal.

  • SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 significantly reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all conditions, SKNY-1 brought anxiety-like behavior back to control or better-than-control levels.

These results suggest SKNY-1 may help stabilize mood and stress-related behavior-a potential advantage in treating both metabolic and addictive disorders.

A New Approach to Endocannabinoid Modulation

SKNY-1 targets the endocannabinoid system (ECS)-a key regulator of hunger, emotion, reward, and addictive behavior-through a multi-pathway approach:

  • Biased CB1 antagonism blocks β-arrestin signaling (linked to cravings and compulsive behavior) while preserving G-protein signaling (important for emotional regulation).

  • CB2 partial agonism may reduce inflammation in the brain, which is increasingly recognized as a driver of anxiety, depression, and cognitive decline. By lowering neuroinflammation, SKNY-1 may help preserve emotional balance and support cognitive resilience.

  • Mild inhibition of MAO-B regulates dopamine, which plays a role in motivation and behavioral control.

  • No inhibition of MAO-A confirmed through in vitro screening-important because MAO-A inhibitors are associated with mood instability, drug interactions, and safety concerns.

This multi-target profile gives SKNY-1 a differentiated mechanism that may allow it to reduce cravings and weight while supporting emotional health-without the psychiatric side effects that limited earlier CB1 or MAO-based drugs.

“The ability to block cravings while preserving emotional balance is a key challenge in this field,” said Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor. “SKNY-1 appears to meet that challenge head-on. The demonstration that its profile is significantly different than rimonabant in its interaction with CB1 agonists, reinforces the unique pharmacological profile of the drug.”

Market Opportunity

Obesity and addiction are among the most urgent and expensive public health challenges globally. In the U.S. alone, the economic burden of obesity and related chronic diseases is estimated at $1.7 trillion annually, equivalent to over 9% of the nation’s GDP (Milken Institute, 2023). Yet despite significant commercial investment, current therapies remain limited by efficacy gaps and tolerability challenges.

Current GLP‑1 therapies like semaglutide deliver weight loss but are injectables, often cause gastrointestinal side effects, and can result in loss of lean muscle mass. Smoking cessation therapies such as varenicline or bupropion offer modest long-term success and may carry psychiatric warnings that restrict their use in sensitive patient populations. Earlier CB1-targeting drugs, including rimonabant, were withdrawn due to severe mood disorders. Furthermore, broad MAO inhibition-especially MAO‑A-has long been associated with mood instability and dangerous food-drug interactions.

SKNY‑1 was developed to address those limitations directly. With oral administration, differentiated pharmacology, and potential dual efficacy in obesity and nicotine addiction, SKNY‑1 may offer a best-in-class profile. Its lack of MAO‑A inhibition, confirmed in vitro, further enhances its therapeutic promise.

Next Steps

MIRA is currently preparing for shareholder approval related to the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1 as a next step toward human clinical trials.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

Helios Secures $4M Seed Round to Build First AI-Native Operating System for Public Policy Professionals

Helios Secures $4M Seed Round to Build First AI-Native Operating System for Public Policy Professionals

Agentic AI platform built for government interaction gives policy and legal teams leverage to move faster, stay ahead of the compliance curve, and outmaneuver red…

July 11, 2025

JTC Team to Host the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

JTC Team to Host the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcasts to be available on-demand Tuesday, July 22nd – Participating company line-up to be announced  – “What’s Your Story” Summer Spotlight promo video…

July 11, 2025

VIEWPOINT: How Thermal Energy Storage Can Maximize the Promise and Instill Safety in Nuclear SMRs

VIEWPOINT: How Thermal Energy Storage Can Maximize the Promise and Instill Safety in Nuclear SMRs

This third installment of Brenmiller Energy’s (NASDAQ:BNRG) “Viewpoint” Series explores how the Company’s bGen™ system can help unlock the full potential of Small Modular Reactor…

July 11, 2025

Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / July 11, 2025 / RedChip Companies will air interviews with Brag House Holdings, Inc. (NASDAQ:TBH) and FibroBiologics, Inc. (NASDAQ:FBLG)…

July 11, 2025

Focus Universal Inc. Starts Internet of Things Production

Focus Universal Inc. Starts Internet of Things Production

ONTARIO, CA / ACCESS Newswire / July 11, 2025 / Focus Universal Inc. (NASDAQ:FCUV) (“Focus” or the “Company”), a provider of patented hardware and software…

July 11, 2025

Gladstone Land Announces  Preferred Stock Repurchase Authorization

Gladstone Land Announces Preferred Stock Repurchase Authorization

MCLEAN, VA / ACCESS Newswire / July 11, 2025 / Gladstone Land Corporation (Nasdaq:LAND) (“Gladstone Land” or the “Company”) announced that its board of directors…

July 11, 2025

Filing Separately Could Cost You More on Back Taxes – Clear Start Tax Explains Smarter Options for Married Couples

Filing Separately Could Cost You More on Back Taxes – Clear Start Tax Explains Smarter Options for Married Couples

Clear Start Tax shows married couples how to avoid costly filing mistakes and save more when back taxes are involved. IRVINE, CA / ACCESS Newswire…

July 11, 2025

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to…

July 11, 2025

Mats for Gym Flooring Now Featured in Expanding Home Fitness Range by Strongway Gym Supplies UK

Mats for Gym Flooring Now Featured in Expanding Home Fitness Range by Strongway Gym Supplies UK

Strongway Gym Supplies continues to serve home fitness users with a broad selection of products built for everyday use. As more people commit to exercising…

July 11, 2025

Northern Superior Enters Into A Definitive Agreement For The Acquisition Of Strategic Properties In The Chibougamau Gold Camp

Northern Superior Enters Into A Definitive Agreement For The Acquisition Of Strategic Properties In The Chibougamau Gold Camp

TORONTO, ON / ACCESS Newswire / July 11, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF)(GR:D9M1) is pleased to announce that,…

July 11, 2025

Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025

Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast…

July 11, 2025

Explore Top Luxury Golf Course Neighborhoods in Las Vegas with RE/MAX United Realtor Leslie Hoke

Explore Top Luxury Golf Course Neighborhoods in Las Vegas with RE/MAX United Realtor Leslie Hoke

Las Vegas Homes By Leslie – RE/MAX United Realtor is excited to announce its latest blog post titled “Discover the Top Luxury Golf Course Neighborhoods…

July 10, 2025

“Your Eyes Could Reveal More Than You Think”: Modern Vision Solutions Highlights the Life-Saving Potential of Routine Eye Exams

“Your Eyes Could Reveal More Than You Think”: Modern Vision Solutions Highlights the Life-Saving Potential of Routine Eye Exams

A new educational article from Modern Vision Solutions reveals a growing body of evidence that underscores the critical role routine eye exams play in identifying…

July 10, 2025

Lee & James Real Estate Photography Launches Back-to-School Special for Portland Area Realtors

Lee & James Real Estate Photography Launches Back-to-School Special for Portland Area Realtors

As summer winds down and families across the Portland metro area gear up for the new school year, Lee & James Real Estate Photography is…

July 10, 2025

Ginza Diamond Shiraishi Hong Kong Presents Curated Wedding Ring Collections Reflecting Japanese Craftsmanship and Cultural Elegance

Ginza Diamond Shiraishi Hong Kong Presents Curated Wedding Ring Collections Reflecting Japanese Craftsmanship and Cultural Elegance

Ginza Diamond Shiraishi Hong Kong, a distinguished branch of the acclaimed Japanese bridal jeweler Ginza Diamond Shiraishi, has reaffirmed its position in the Hong Kong…

July 10, 2025

Cobalt Keys LLC Revolutionizes Digital Marketing with Cutting-Edge AI and Automation Strategies

Cobalt Keys LLC Revolutionizes Digital Marketing with Cutting-Edge AI and Automation Strategies

Cobalt Keys LLC’s company website provides a wealth of information on their specialized services. Explore more about how they employ advanced AI solutions to analyze…

July 10, 2025

Convert Peak Launches Phonetix A.I. to Transform Roofing Sales with Voice-Driven Automation

Convert Peak Launches Phonetix A.I. to Transform Roofing Sales with Voice-Driven Automation

New Voice AI Assistant Gives Roofing Contractors a Competitive Edge in Storm-Damage Sales SCOTTSDALE, AZ / ACCESS Newswire / July 10, 2025 / Roofing contractors…

July 10, 2025

Terra Innovatum to Participate in Upcoming H.C. Wainwright Virtual Conference on July 15, 2025

Terra Innovatum to Participate in Upcoming H.C. Wainwright Virtual Conference on July 15, 2025

NEW YORK, NY and AUSTIN, TX / ACCESS Newswire / July 10, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of…

July 10, 2025

Gladstone Land Announces Monthly Cash Distributions for July, August and September 2025 and Earnings Release and Conference Call Dates for the Second Quarter Ended June 30, 2025

Gladstone Land Announces Monthly Cash Distributions for July, August and September 2025 and Earnings Release and Conference Call Dates for the Second Quarter Ended June 30, 2025

MCLEAN, VA / ACCESS Newswire / July 10, 2025 / Gladstone Land Corporation (Nasdaq:LAND) (“Gladstone Land” or the “Company”) announced today that its board of…

July 10, 2025

Gladstone Commercial Corporation Announces Monthly Cash Distributions for July, August and September 2025 and Earnings Release and Conference Call Dates for its Second Quarter Ended June 30, 2025

Gladstone Commercial Corporation Announces Monthly Cash Distributions for July, August and September 2025 and Earnings Release and Conference Call Dates for its Second Quarter Ended June 30, 2025

MCLEAN, VA / ACCESS Newswire / July 10, 2025 / Gladstone Commercial Corporation (Nasdaq:GOOD) (the “Company”) announced today that its board of directors declared cash…

July 10, 2025

Gladstone Investment Announces Monthly Cash Distributions for July, August and September 2025, and Earnings Release and Conference Call Dates for the First Fiscal Quarter

Gladstone Investment Announces Monthly Cash Distributions for July, August and September 2025, and Earnings Release and Conference Call Dates for the First Fiscal Quarter

MCLEAN, VA / ACCESS Newswire / July 10, 2025 / Gladstone Investment Corporation (Nasdaq:GAIN) (the “Company”) announced today that its board of directors declared the…

July 10, 2025

Gladstone Capital Announces Monthly Cash Distributions for July, August and September 2025 and Conference Call Date

Gladstone Capital Announces Monthly Cash Distributions for July, August and September 2025 and Conference Call Date

MCLEAN, VA / ACCESS Newswire / July 10, 2025 / Gladstone Capital Corporation (Nasdaq:GLAD) (the “Company”) announced today that its board of directors declared the…

July 10, 2025

Legacy in Motion: Preparing the Next Generation at Bradley Wealth

Legacy in Motion: Preparing the Next Generation at Bradley Wealth

SCOTTSDALE, AZ / ACCESS Newswire / July 10, 2025 / Michael Bradley has spent more than 30 years building one of the most trusted independent…

July 10, 2025

Transforming Garland, TX: Lone Wolf Exteriors Elevates Community with Vinyl Siding Initiative

Transforming Garland, TX: Lone Wolf Exteriors Elevates Community with Vinyl Siding Initiative

Lone Wolf Exteriors has announced an exciting partnership with a leading nonprofit to enhance its community outreach efforts. Having established itself as a reputable provider…

July 10, 2025

Apex Money Lending Group Boosts Small Business Growth with New Loan Options in Colorado

Apex Money Lending Group Boosts Small Business Growth with New Loan Options in Colorado

Apex Money Lending Group LLC is now offering flexible loan options to better assist small business owners. Understanding the struggles entrepreneurs face when seeking funding,…

July 10, 2025

APS Environmental Expands Dumpster Rentals to Meet East Sacramento’s Rising Waste Disposal Needs

APS Environmental Expands Dumpster Rentals to Meet East Sacramento’s Rising Waste Disposal Needs

APS Environmental is expanding its dumpster rental services into East Sacramento to meet the rising demand for efficient waste disposal in the area. This move…

July 10, 2025

CoreStack Achieves Microsoft Solutions Partner Designation With Azure Certified Software for Its NextGen Cloud Governance and Security Platform

CoreStack Achieves Microsoft Solutions Partner Designation With Azure Certified Software for Its NextGen Cloud Governance and Security Platform

BELLEVUE, WA / ACCESS Newswire / July 10, 2025 / CoreStack, a leading provider of NextGen Cloud Optimization, and Governance and Security, today announced it…

July 10, 2025

Agent Boost Marketing Joins Forces with AmeriLife’s Senior Market Advisors

Agent Boost Marketing Joins Forces with AmeriLife’s Senior Market Advisors

Partnership creates geographic advantages aligned with SMA’s strategic growth plan while diversifying the distribution of individual insurance products NASHVILLE, TENN. AND CLEARWATER, FLA. / ACCESS…

July 10, 2025

Voices Announces Upcoming Launch, Unveiling Voice Data Solution to Power Responsible Voice AI

Voices Announces Upcoming Launch, Unveiling Voice Data Solution to Power Responsible Voice AI

NEW YORK, NY / ACCESS Newswire / July 10, 2025 / Voices, the world’s most comprehensive voice solutions provider, today announced it will officially be…

July 10, 2025

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization…

July 10, 2025

Abacus Raises $6.6M Seed Round to Build Agentic CPA Assistants for the Modern Accounting Firm

Abacus Raises $6.6M Seed Round to Build Agentic CPA Assistants for the Modern Accounting Firm

Menlo Ventures leads round backing intelligent assistants that help tax firms scale amid rising workloads and shrinking headcount. SAN FRANCISCO, CA / ACCESS Newswire /…

July 10, 2025

Brenmiller Energy Releases Annual ESG Report Highlighting Commercial Expansion, Carbon Tracking, and Sustainable Innovation

Brenmiller Energy Releases Annual ESG Report Highlighting Commercial Expansion, Carbon Tracking, and Sustainable Innovation

Report details progress in Environmental, Social, and Governance priorities and strengthens investor transparency The full ESG report is available: HERE To view Brenmiller’s latest investor…

July 10, 2025

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19…

July 10, 2025

Arrive AI selects Synoptek as a Strategic IT Partner to Power Global Expansion

Arrive AI selects Synoptek as a Strategic IT Partner to Power Global Expansion

INDIANAPOLIS, IN AND COSTA MESA, CA / ACCESS Newswire / July 10, 2025 / Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by…

July 10, 2025

Electrovaya Achieves UL2580 Certification for Over 400 Next-Generation Lithium-Ion Battery Models

Electrovaya Achieves UL2580 Certification for Over 400 Next-Generation Lithium-Ion Battery Models

Latest battery systems feature enhanced performance and include 54Ah ceramic cell to be mass produced in Jamestown, NY Passed the most stringent safety testing in…

July 10, 2025

Not a LASIK Candidate: Kugler Vision Offers Alternatives in Vision Correction for Omaha Patients

Not a LASIK Candidate: Kugler Vision Offers Alternatives in Vision Correction for Omaha Patients

For many patients, the idea of LASIK represents the end of glasses or contact lenses and the beginning of clearer vision. But for some, a…

July 9, 2025

Go Industries Launches Medium Duty Grille Guards for Trucks: Elevating Safety and Style with Easy Installation

Go Industries Launches Medium Duty Grille Guards for Trucks: Elevating Safety and Style with Easy Installation

Go Industries Inc., known for its truck accessories and law enforcement gear, has excitedly launched its new Medium Duty grille guard designed for vehicles like…

July 9, 2025

Unusual Machines Expands Leadership Team with Appointment of Tim Manton as Corporate Controller

Unusual Machines Expands Leadership Team with Appointment of Tim Manton as Corporate Controller

New hire supports operational scale-up and financial infrastructure as company ramps U.S. motor manufacturing ORLANDO, FLORIDA / ACCESS Newswire / July 9, 2025 / Unusual…

July 9, 2025

Front Range Pharmacy Reinforces Commitment to Medication Adherence with DayPacks Pre-Packaged Service

Front Range Pharmacy Reinforces Commitment to Medication Adherence with DayPacks Pre-Packaged Service

Front Range Pharmacy, a trusted community pharmacy located in Englewood, Colorado, is proud to reaffirm its commitment to personalized patient care through its innovative DayPacks…

July 9, 2025

APS Environmental Launches Comprehensive Dumpster Rentals in El Dorado Hills for Residential and Commercial Needs

APS Environmental Launches Comprehensive Dumpster Rentals in El Dorado Hills for Residential and Commercial Needs

APS Environmental is adding dumpster rental services to its lineup in Northern California. This move aligns with the company’s goal of offering comprehensive environmental solutions…

July 9, 2025